ACERUS OTC Stock Probability of Future OTC Stock Price Finishing Over 0.029

ASPCF -  USA Stock  

USD 0.029  0.00  0.00%

ACERUS PHARMACEUTICALS's future price is the expected price of ACERUS PHARMACEUTICALS instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of ACERUS PHARMACEUTICALS CORP performance during a given time horizon utilizing its historical volatility.

Search Price Probability 

 
Refresh
Please continue to Trending Equities.Please specify ACERUS PHARMACEUTICALS time horizon, a valid symbol (red box) and a target price (blue box) you would like ACERUS PHARMACEUTICALS odds to be computed.
Apply Odds

ACERUS PHARMACEUTICALS Target Price Odds to finish over 0.029

The tendency of ACERUS OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for foresting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.029 90 days 0.029  under 95
Based on a normal probability distribution, the odds of ACERUS PHARMACEUTICALS to move above the current price in 90 days from now is under 95 (This ACERUS PHARMACEUTICALS CORP probability density function shows the probability of ACERUS OTC Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon the otc stock has the beta coefficient of 1.24 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, ACERUS PHARMACEUTICALS will likely underperform. Additionally The company has an alpha of 0.6704, implying that it can generate a 0.67 percent excess return over DOW after adjusting for the inherited market risk (beta).
 ACERUS PHARMACEUTICALS Price Density 
      Price 

Predictive Modules for ACERUS PHARMACEUTICALS

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ACERUS PHARMACEUTICALS. Regardless of method or technology, however, to accurately forecast the stock or bond market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of ACERUS PHARMACEUTICALS's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of ACERUS PHARMACEUTICALS in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
0.030.030.03
Details
Intrinsic
Valuation
LowReal ValueHigh
0.030.0269220.03
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as ACERUS PHARMACEUTICALS. Your research has to be compared to or analyzed against ACERUS PHARMACEUTICALS's peers to derive any actionable benefits. When done correctly, ACERUS PHARMACEUTICALS's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in ACERUS PHARMACEUTICALS.

ACERUS PHARMACEUTICALS Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. ACERUS PHARMACEUTICALS is not an exception. The market had few large corrections towards the ACERUS PHARMACEUTICALS's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ACERUS PHARMACEUTICALS CORP, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ACERUS PHARMACEUTICALS within the framework of very fundamental risk indicators.
α
Alpha over DOW
0.67
β
Beta against DOW1.24
σ
Overall volatility
0.004439
Ir
Information ratio 0.05

ACERUS PHARMACEUTICALS Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ACERUS PHARMACEUTICALS for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ACERUS PHARMACEUTICALS can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
ACERUS PHARMACEUTICALS is not yet fully synchronised with the market data
ACERUS PHARMACEUTICALS has some characteristics of a very speculative penny stock
ACERUS PHARMACEUTICALS has high likelihood to experience some financial distress in the next 2 years
The company has accumulated 13.16 M in total debt with debt to equity ratio (D/E) of 2.61, implying the company greatly relies on financing operations through barrowing. ACERUS PHARMACEUTICALS has a current ratio of 0.66, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
The entity reported the revenue of 1.56 M. Net Loss for the year was (34.05 M) with loss before overhead, payroll, taxes, and interest of (929 K).
ACERUS PHARMACEUTICALS CORP has accumulated about 2.6 M in cash with (23.57 M) of positive cash flow from operations.
Roughly 91.0% of ACERUS PHARMACEUTICALS shares are held by company insiders

ACERUS PHARMACEUTICALS Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ACERUS OTC Stock often depends not only on the future outlook of the current and potential ACERUS PHARMACEUTICALS's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ACERUS PHARMACEUTICALS's indicators that are reflective of the short sentiment are summarized in the table below.
Float Shares132.59M
Average Daily Volume Last 10 Day1.86k
Average Daily Volume In Three Month10.2k

ACERUS PHARMACEUTICALS Technical Analysis

ACERUS PHARMACEUTICALS's future price can be derived by breaking down and analyzing its technical indicators over time. ACERUS OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of ACERUS PHARMACEUTICALS CORP. In general, you should focus on analyzing ACERUS OTC Stock price patterns and their correlations with different microeconomic environments and drivers.

ACERUS PHARMACEUTICALS Predictive Forecast Models

ACERUS PHARMACEUTICALS time-series forecasting models is one of many ACERUS PHARMACEUTICALS's otc stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ACERUS PHARMACEUTICALS's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about ACERUS PHARMACEUTICALS

Checking the ongoing alerts about ACERUS PHARMACEUTICALS for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for ACERUS PHARMACEUTICALS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

ACERUS PHARMACEUTICALS Alerts

ACERUS PHARMACEUTICALS Alerts and Suggestions

ACERUS PHARMACEUTICALS is not yet fully synchronised with the market data
ACERUS PHARMACEUTICALS has some characteristics of a very speculative penny stock
ACERUS PHARMACEUTICALS has high likelihood to experience some financial distress in the next 2 years
The company has accumulated 13.16 M in total debt with debt to equity ratio (D/E) of 2.61, implying the company greatly relies on financing operations through barrowing. ACERUS PHARMACEUTICALS has a current ratio of 0.66, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
The entity reported the revenue of 1.56 M. Net Loss for the year was (34.05 M) with loss before overhead, payroll, taxes, and interest of (929 K).
ACERUS PHARMACEUTICALS CORP has accumulated about 2.6 M in cash with (23.57 M) of positive cash flow from operations.
Roughly 91.0% of ACERUS PHARMACEUTICALS shares are held by company insiders
Please continue to Trending Equities. Note that the ACERUS PHARMACEUTICALS information on this page should be used as a complementary analysis to other ACERUS PHARMACEUTICALS's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for ACERUS OTC Stock analysis

When running ACERUS PHARMACEUTICALS price analysis, check to measure ACERUS PHARMACEUTICALS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACERUS PHARMACEUTICALS is operating at the current time. Most of ACERUS PHARMACEUTICALS's value examination focuses on studying past and present price action to predict the probability of ACERUS PHARMACEUTICALS's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move ACERUS PHARMACEUTICALS's price. Additionally, you may evaluate how the addition of ACERUS PHARMACEUTICALS to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
The market value of ACERUS PHARMACEUTICALS is measured differently than its book value, which is the value of ACERUS that is recorded on the company's balance sheet. Investors also form their own opinion of ACERUS PHARMACEUTICALS's value that differs from its market value or its book value, called intrinsic value, which is ACERUS PHARMACEUTICALS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACERUS PHARMACEUTICALS's market value can be influenced by many factors that don't directly affect ACERUS PHARMACEUTICALS underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACERUS PHARMACEUTICALS's value and its price as these two are different measures arrived at by different means. Investors typically determine ACERUS PHARMACEUTICALS value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACERUS PHARMACEUTICALS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.